Mirnela Byku, and Douglas L. Mann BTS 2016;1:95-106

Slides:

Advertisements

Similar presentations

Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy.

Advertisements

prognosis of patients with Acute Myocardial Infarction remains dismal.

Copyleft Clinical Trial Results. You Must Redistribute Slides SEISMIC Trial The Safetyand Effects of Implanted (Autologous) Skeletal Myoblasts (MyoCell)

Sudden Cardiac Death in Heart Failure Trial Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Gust H. Bardy SCD-HeFTSCD-HeFT.

Presenter Disclosure Information John F. Beshai, MD RethinQ Trial Results Disclosures Information: The following relationships exist related to this presentation:

Target Study Cardiac resynchronization therapy (CRT) is an established treatment for advanced heart failure symptoms, impaired LV systolic function, and.

Effects of PG , a Matrix Metalloproteinase Inhibitor to Prevent Left Ventricular Remodeling After Acute Myocardial Infarction Effects of PG ,

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Efficacy and safety of ivabradine in patients with severe chronic systolic.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Selective heart rate reduction with ivabradine unloads the left ventricle in.

Charlotte Kragelund et al N Engl J Med 2005;352: Baseline Clinical Characteristics According to Quartiles of NT-pro-BNP.

Candesartan in Heart Failure Presented at European Society of Cardiology 2003 CHARM Trial.

COPERNICUS: Carvedilol Prospective Randomized Cumulative Survival trial Purpose To assess the effect of carvedilol, a β 1 -, β 2 - and α 1 -receptor blocker,

Date of download: 6/25/2016 Copyright © 2016 American Medical Association. All rights reserved. From: BNP-Guided vs Symptom-Guided Heart Failure Therapy:

Date of download: 6/26/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Influence of Left Ventricular Ejection Fraction.

Treatment options for patients with chronic symptomatic systolic heart failure. ACE, angiotensinconvertingenzyme; ARB, angiotensin receptor blocker; CRT-D,

Management of mitral regurgitation. See legend for Fig

Treatment options for patients with chronic symptomatic systolic heart failure. ACE, angiotens inconverting enzyme; ARB, angiotensin receptor blocker;

– р<0.05 between baseline

Figure 1 Representative longitudinal strain analysis in an apical two-chamber view. The view is presented in the left panel and the longitudinal strain.

Echocardiographic modalities for evaluation and risk stratification of heart failure patients. 3D indicates 3-dimensional; EF, ejection fraction; LA, left.

Chronic Vagus Nerve Stimulation Improves Autonomic Control and Attenuates Systemic Inflammation and Heart Failure Progression in a Canine High-Rate Pacing.

Optimal Pacing for Right Ventricular and Biventricular Devices

by Peter J. Schwartz, Maria Teresa La Rovere, Gaetano M

Erratum Heart Rhythm Volume 8, Issue 4, (April 2011)

Left ventricular dysfunction after mitral valve repair—the fallacy of “normal” preoperative myocardial function Eduard Quintana, MD, Rakesh M. Suri,

Propensity Scores: Uses and Limitations

Volume 12, Issue 3, Pages (March 2015)

The STICH trial: Misguided conclusions

INOVATE-HF Trial design: Patients with heart failure (HF) were randomized to device implant for vagus nerve stimulation (n = 436) versus optimal medical.

Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.

Daniel J. Lenihan et al. BTS 2016;1:

Shadi Al Halabi et al. JACEP 2015;1:

Nat. Rev. Cardiol. doi: /nrcardio

G. Michael Felker et al. JCHF 2014;2:

Mirnela Byku, and Douglas L. Mann BTS 2016;1:95-106

Autonomic Regulation Therapy for the Improvement of Left Ventricular Function and Heart Failure Symptoms: The ANTHEM-HF Study Rajendra K. Premchand, Kamal.

Angelo Auricchio, and Frits W. Prinzen JACEP 2017;3:

BAT for HFrEF Trial design: Patients with chronic systolic HF were randomized in a 1:1 fashion to either baroreceptor activation therapy (BAT) or control.

Nat. Rev. Cardiol. doi: /nrcardio

Douglas L. Mann, MD, Michael A. Acker, MD, Mariell Jessup, MD, Hani N

Juan A. Crestanello, MD, Richard C. Daly, MD

Mirnela Byku, and Douglas L. Mann BTS 2016;1:95-106

The effect of GOODCOLL versus POORCOLL on LVEF, LVEDV and scar at 4 months. The effect of GOODCOLL versus POORCOLL on LVEF, LVEDV and scar at 4 months.

Nikole J. Byrne et al. BTS 2017;j.jacbts

Figure 1 Study flow diagram and definition of clinical response

Angelo Auricchio, and Frits W. Prinzen JACEP 2017;j.jacep

Is subvalvular repair worthwhile in severe ischemic mitral regurgitation? Subanalysis of the Papillary Muscle Approximation trial Francesco Nappi, MD,

Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effect of ivabradine on recurrent hospitalization for worsening heart failure:

Mitral valve repair in heart failure: Five-year follow-up from the mitral valve replacement stratum of the Acorn randomized trial Michael A. Acker, MD,

Nat. Rev. Cardiol. doi: /nrcardio

Emilce Trucco et al. JACEP 2018;j.jacep

Romain Gallet et al. BTS 2016;1:14-28

LV Structure, Function, and Circulating BNP Levels at 18 Weeks Post TAC (A) (B) LVEDD and LVESD (mm) throughout the experimental protocol. (C) Percent.

Eduardo Marbán, MD, PhD Mayo Clinic Proceedings

Helena M. Viola et al. BTS 2018;3:

Time course of changes in left ventricular ejection fraction (LVEF) and left ventricular diastolic dimension (LVDd) in 13 patients with the development.

Cumulative survival without events during 1 year in patients with preserved systolic function (left ventricular ejection fraction (LVEF) >40%) and with.

Patient selection. *This category included 10 patients with suspected tachyarrhythmia, 9 treated for cancer with cardiotoxic cytostatics and/or transthoracic.

Associations between presence of tachycardia at time of admission (heart rate ≥120/min) and the primary composite outcome of death or cardiovascular rehospitalisation,

Absolute mortality difference Change in LVEF from baseline

Connie W. Tsao et al. JCHF 2016;4:

Average left ventricular ejection fraction (LVEF) values during the 1 year of observation in patients with preserved systolic function (LVEF >40%) and.

Unadjusted means by smoking status

Lifetime heart failure risk*

William T. Abraham et al. JCHF 2018;j.jchf

Rick A. Nishimura et al. JACC 2017;70:

Histograms of LVESVI, LVEDVI, LVMI, and 3D LVEF Tabulations of frequencies of left ventricular end-systolic volume (A), end-diastolic volume (B), mass.

Time to first event analysis revealed a significant difference in estimated event-free (death or hospitalisation) survival between patients with left ventricular.

Patient selection process in the present study.

Change in 6 min walk distance at 12 months in subgroups defined by baseline characteristics. The mean (95% CI) for the difference between CABG and medical.

Presentation transcript:

Mirnela Byku, and Douglas L. Mann BTS 2016;1:95-106 Primary Clinical Endpoint of the ANTHEM-HF Trial Mean and 95% confidence intervals of echocardiographic changes after 6 months of autonomic regulation therapy (overall, left-side treatment, and right-side treatment). Reproduced with permission from Premchand RK et al. (23). ANTHEM-HF = Autonomic Regulation Therapy via Left or Right Cervical Vagus Nerve Stimulation in Patients With Chronic Heart Failure; LVEF = left ventricular ejection fraction; LVESV = left ventricular end-systolic volume; LVESD = left ventricular end-systolic diameter. Mirnela Byku, and Douglas L. Mann BTS 2016;1:95-106 The Authors